NovoCure Ltd. ((NVCR)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NovoCure Ltd. is conducting a pivotal study titled ‘EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma.’ The study aims to assess the effectiveness and safety of the Optune® device when used alongside radiation therapy and temozolomide in patients with newly diagnosed glioblastoma, compared to the standard treatment of radiation therapy and temozolomide alone. This study is significant as it explores the potential for improved clinical outcomes by introducing Optune® earlier in the treatment process.
The intervention being tested is the Optune® device, a portable, battery-operated device that delivers Tumor Treating Fields (TTFields) at 200kHz to the brain. It is designed to disrupt cancer cell division and is intended for continuous home use.
The study employs a randomized, parallel intervention model with no masking, focusing primarily on treatment. Participants are randomly assigned to one of two groups: one receiving Optune® alongside radiation therapy and temozolomide, and the other receiving only radiation therapy and temozolomide initially, followed by Optune®.
The study began on December 8, 2020, and is currently active but not recruiting. The last update was submitted on August 4, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This study update could influence NovoCure’s stock performance and investor sentiment, as positive results may enhance the company’s market position in the glioblastoma treatment sector. It also highlights the competitive landscape, where advancements in treatment options are closely watched by investors.
The study is ongoing, with further details available on the ClinicalTrials portal.